Skip to content
lifestyle.thriveinsider.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
HOTH THERAPEUTICS, INC.
Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery
March 26, 2026
Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption
March 24, 2026
Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model
March 10, 2026
Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program
March 4, 2026
HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES
February 24, 2026
Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases
February 12, 2026
Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth’s HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model
February 12, 2026
Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets
February 10, 2026
Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients
January 23, 2026
Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position
January 21, 2026
←
Previous Page
1
2
3
Next Page
→